A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2017
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Leiomyosarcoma; Liposarcoma; Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- 23 Aug 2017 Status changed from not yet recruiting to suspended as additional pre-registration requirements needed.
- 14 Aug 2017 Planned initiation date changed from 4 Aug 2017 to 15 Sep 2017.
- 10 Jun 2017 Biomarkers information updated